Investigational New Drug

Based on Wikipedia: Investigational New Drug

The Thirty-Day Clock

Somewhere in the United States right now, a pharmaceutical company is watching a calendar. They submitted paperwork to the Food and Drug Administration exactly twenty-three days ago, and in seven more days, if nobody objects, they can inject an experimental compound into a human being for the first time. This is the Investigational New Drug application process, and that thirty-day window is one of the most consequential waiting periods in medicine.

The IND is how drugs escape the laboratory and enter the human body. Before a company can ship an experimental medicine across state lines, before a doctor can administer something that has only ever been tested on mice and monkeys, someone at the FDA has to decide not to stop it.

Notice that phrasing: decide not to stop it. The system works on implicit approval. Submit your application, wait thirty days, and if you don't hear anything, you're cleared to begin. This design reflects a fundamental tension in drug regulation—the desperate need for new treatments versus the imperative to protect people from harm.

What Goes Into an IND

An IND application is essentially a company's argument that they've done enough homework to justify experimenting on people. The application has several core components, each designed to answer a different question.

First comes the preclinical data. This is everything you learned from animal studies—how the drug behaves in living systems, what doses cause problems, which organs seem vulnerable. If you gave this compound to rats and their livers failed, you need to explain why you think human livers will fare better. Sometimes applicants include data from human use in other countries, which raises interesting questions about the global patchwork of drug regulation.

Then there's manufacturing information. This might seem bureaucratic, but it matters enormously. The FDA wants to know that you can actually produce consistent batches of your drug. If batch number one cured cancer but batch number two was somehow contaminated or chemically different, your clinical trial results become meaningless. Drug development has been derailed by manufacturing problems more often than you might expect.

The application also includes information about the investigators—the doctors and researchers who will actually run the clinical trials. Are they qualified? Do they have the right credentials and experience? Have they done this before? The FDA is essentially vetting the people who will be responsible for the safety of study participants.

But the centerpiece of any IND is the clinical trial protocol itself. This document describes exactly what you plan to do: how many people, what doses, what you'll measure, how long the study will last. The FDA scrutinizes this to determine whether your first-in-human trials will expose subjects to unnecessary risks.

The Different Flavors of INDs

Not all INDs are created equal. The most common type is what you might call a commercial IND—a pharmaceutical company developing a drug they hope to eventually sell. But there are several other varieties, each serving a different purpose.

Research INDs, sometimes called investigator INDs, are filed by academic researchers rather than companies. Maybe a university scientist wants to study whether an existing drug might work for a completely different disease than it was approved for. This happens constantly in medicine—drugs often turn out to have unexpected benefits for conditions nobody anticipated.

Emergency Use INDs exist for desperate situations. When someone is dying and no approved treatment exists, there isn't always time for the normal application process. These INDs, also called compassionate use or single-patient INDs, allow doctors to try experimental drugs when the clinical situation simply won't wait. The paperwork happens, but it happens faster and with different requirements.

Treatment INDs occupy a middle ground. These make unapproved drugs available for serious or life-threatening conditions before the FDA has formally approved them. The regulations specifically list qualifying conditions: stroke, schizophrenia, rheumatoid arthritis, chronic depression, seizures, Alzheimer's disease, amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and narcolepsy, among others. These are conditions where the suffering is severe enough that regulators accept more uncertainty about the treatment.

Finally, screening INDs allow companies to test multiple closely related compounds to figure out which one works best. Drugs often come in families—different chemical variations that behave similarly but might have meaningful differences in how well they work or what side effects they cause. A screening IND lets you compare them head-to-head before committing to develop one specific version.

The Investigator's Brochure

Every IND application must include something called an Investigator's Brochure. This document is essentially a comprehensive briefing for the doctors who will run the clinical trials.

Think of it this way: you're asking a physician to inject a substance into their patients that has never been tested in humans before. They need to understand everything relevant about that substance. What does it do? What might go wrong? What warning signs should they watch for? What do the animal studies suggest about potential risks?

The Investigator's Brochure compiles all this information into one place. It's meant to ensure that the people administering experimental drugs understand enough to minimize hazards to their patients. Good medical judgment requires good information, and the brochure is how that information gets transmitted from the drug developer to the clinical investigator.

The Clinical Hold

What happens if the FDA does object during that thirty-day window?

The agency can place what's called a clinical hold on an IND. This stops the clinical studies before they start. The company can't proceed until the identified problem is resolved—whatever safety concern, data gap, or protocol flaw triggered the hold.

Clinical holds can also happen after trials have begun, if the FDA discovers new information suggesting participants might be at risk. This is one of the agency's most powerful tools for protecting human subjects in research.

The regulations governing clinical holds live in Title 21 of the Code of Federal Regulations, section 312.42. This level of specificity matters because drug development is fundamentally a legal and regulatory exercise as much as a scientific one. Every step has its corresponding regulation, its required documentation, its potential points of failure.

The Label

Here's a detail that captures something essential about investigational drugs. Every bottle, vial, or package of an IND must carry a specific label: "Caution: New Drug – Limited by Federal (or United States) law to investigational use."

That label is a boundary marker. It separates the world of approved medicines from the world of experimental ones. An approved drug can be prescribed by any licensed physician for any patient they deem appropriate. An investigational drug exists only within the carefully controlled context of a clinical trial, with its protocols and oversight and data collection.

The labeling requirement reminds everyone involved—doctors, nurses, patients, pharmacists—that this substance hasn't yet earned the FDA's approval. Whatever promise it shows, whatever hope it offers, it remains an experiment.

Success Rates and Reality

About half of all INDs fail.

That number should give you pause. After all the preclinical research, after all the animal testing, after assembling the massive documentation package required for an IND application, roughly fifty percent of investigational drugs still don't make it through clinical development.

The failures happen for various reasons. Sometimes the drug simply doesn't work in humans the way it worked in animals—biology is more complex than any model can capture. Sometimes unexpected side effects emerge that make the drug too dangerous. Sometimes the drug works but not well enough to justify the risks. Sometimes manufacturing problems prove insurmountable at commercial scale.

Two-thirds of both INDs and the subsequent New Drug Applications (the final approval step) involve small-molecule drugs—traditional chemical compounds that can often be manufactured as pills. The remaining third are biopharmaceuticals, larger and more complex molecules that usually require injection and careful temperature control.

International Harmonization

The IND process isn't unique to the United States. The European Union, Japan, and Canada all have similar procedures, and they've grown increasingly aligned over time.

This alignment isn't accidental. An organization called the International Council for Harmonisation (formerly the International Conference on Harmonisation, though the acronym ICH stuck) has worked for decades to standardize drug development requirements across major markets. The goal is efficiency: if a company can run a single clinical trial that satisfies regulators in multiple countries, drug development becomes faster and cheaper.

From a practical standpoint, this means that pharmaceutical companies can often use similar documentation and study designs for submissions in different countries. The underlying science doesn't change at national borders, after all. A drug that's safe and effective in American patients will generally be safe and effective in European or Japanese patients too.

Compassionate Use and Its Limits

The emergency use pathway raises difficult ethical questions. If someone is dying and an experimental drug might help, shouldn't they have access to it?

The intuitive answer is yes. But the situation is more complicated than it appears.

Emergency access to unapproved drugs can undermine the clinical trials needed to prove those drugs actually work. If patients can get experimental treatments outside of trials, they have less incentive to enroll in studies. And without completed trials, we never learn whether the drugs are genuinely effective or merely hopeful.

There's also the question of false hope. An experimental drug is, by definition, unproven. Giving it to a dying patient doesn't mean it will help. It might do nothing. It might cause harm. The desperation of the dying and their families can create enormous pressure to try anything, even when the scientific basis for optimism is thin.

Organizations like the Abigail Alliance for Better Access to Developmental Drugs have advocated for broader access to experimental treatments. The alliance was founded after a young woman named Abigail Burroughs died from cancer while drugs that might have helped her remained locked in clinical trials. Her case and others like it have shaped ongoing debates about the right balance between access and evidence.

The Medical Marijuana Program

One of the stranger chapters in IND history involves cannabis.

The FDA ran a medical marijuana IND program—the Compassionate Investigational New Drug program—that provided government-grown cannabis to patients with certain conditions. The program was small and eventually controversial.

In 1992, the program stopped accepting new patients. Public health authorities had concluded it offered no scientific value, and the George H.W. Bush administration wanted to project a tough-on-crime stance that was inconsistent with the government literally growing and distributing marijuana.

But the program didn't quite end. Patients already enrolled were allowed to continue receiving their government cannabis. As of 2011, four patients were still getting regular shipments of marijuana from a federal facility in Mississippi. The program had become a strange artifact—a handful of people grandfathered into a system that no longer existed for anyone else.

Military Exceptions

Another unusual IND case involved the Department of Defense and anthrax vaccines.

Under Executive Order 13139, the military used an anthrax vaccine classified as an investigational new drug in its Anthrax Vaccine Immunization Program. This meant soldiers were receiving a vaccine that hadn't completed the normal FDA approval process for its intended use.

The situation raised profound questions about informed consent and military service. Can you truly consent to an experimental medical intervention when refusing might end your military career? The controversy led to lawsuits, policy changes, and ongoing debates about the intersection of national security and drug regulation.

The Broader System

The IND process is just one piece of a larger regulatory architecture. Before an IND, there's drug discovery—the initial identification of a promising compound, often through years of basic research. After successful clinical trials come various approval pathways.

For most drugs, the endpoint is a New Drug Application, another massive documentation package that reviews all the clinical trial data and asks the FDA to approve the drug for sale. For biological products like vaccines and blood products, the equivalent is a Biologics License Application. For veterinary medicines, different rules apply entirely.

The FDA also maintains various expedited pathways for especially promising or needed drugs. The Fast Track Development Program accelerates review for drugs treating serious conditions with unmet medical needs. Breakthrough Therapy designation provides even more intensive FDA guidance for drugs showing dramatic early results. Priority Review shortens the FDA's review timeline for important new drugs.

Orphan drug designation encourages development of treatments for rare diseases that might otherwise be commercially unviable. The economic incentives of pharmaceutical development naturally favor common conditions with large patient populations. Orphan drug rules—including extended market exclusivity and tax credits—try to counterbalance this tendency.

The Drug Lag Debate

Every drug regulatory system faces the same fundamental tradeoff. More rigorous review protects patients from dangerous or ineffective drugs but delays access to beneficial ones. Faster review gets good drugs to patients sooner but risks approving harmful ones.

Economists have a term for the costs of excessive caution: drug lag. This refers to the delay between when a drug becomes available in one country versus another, or between when a drug could have been approved and when it actually was.

Drug lag has real human costs. People die while waiting for treatments that could have saved them. But the alternative—approving drugs too quickly—has its own death toll. The history of medicine includes disasters like thalidomide, a drug that caused severe birth defects in thousands of children before regulators removed it from the market.

The IND process represents one society's attempt to navigate this tradeoff. The thirty-day automatic approval, the clinical hold mechanism, the emergency use pathways—all of these reflect judgments about acceptable risk and the proper pace of medical innovation. Different countries have reached different conclusions, and even within the United States, the balance has shifted over time in response to drug disasters and advocacy movements alike.

Looking Forward

The basic IND framework has remained relatively stable for decades, but the drugs themselves have changed dramatically. Gene therapies, cell therapies, personalized medicine—these create new challenges that the existing regulatory structure sometimes struggles to address.

How do you run a traditional clinical trial for a treatment designed for a single patient's specific genetic profile? How do you ensure manufacturing consistency when the "drug" is actually living cells? What preclinical data is relevant when the treatment mechanism has no animal analog?

These questions don't have easy answers. The FDA continues to adapt its guidance, creating new pathways and frameworks for novel therapeutic categories. The fundamental goal remains the same as it was when the IND process was first established: protect people from harm while giving them access to treatments that might help.

That thirty-day clock keeps ticking, somewhere, for drugs we've never heard of that might someday change medicine. The waiting period is short in calendar terms but represents years of prior work and potentially years of future development. It's a threshold moment, the boundary between laboratory promise and human reality, managed by a regulatory process that few people think about but that shapes the medicines available to all of us.